Education
About Us
Working with TipRanks
Follow Us
Marker Therapeutics (MRKR)
:MRKR
MRKR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.95 - $5.95
Previous CloseN/A
Volume39.59K
Average Volume (3M)2.36M
Market Cap
$14.14M
Enterprise Value-$32.79K
Total Cash (Recent Filing)$13.69M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Aug 18, 2025EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,314,835
10 Day Avg. Volume165,957
30 Day Avg. Volume2,360,307
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)<0.01
Price to Sales (P/S)4.24
P/FCF Ratio-2.56
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$8.00Price Target Upside534.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical DataThe initial readout showed a high overall response rate and complete remission rate in B-Cell lymphoma patients who failed or were ineligible for CD19.
Manufacturing CollaborationThe collaboration with Cellipont lowers manufacturing risk, and allows for easier future expansion for Marker's MT-601.
Market OpportunityMarker sees a reasonable commercial opportunity for CAR-T relapsed patients in lymphoma due to the company's differentiated multi-antigen targeting approach.
Bears Say
FundingMRKR secured more than $13 million in non-dilutive funding in 2024 to advance its lead product MT-601.
Regulatory RiskCellipont, a leading Contract Development and Manufacturing Organization (CDMO), will manufacture MT-601 in a more effective and consistent manner vs Baylor for the pivotal study, reducing regulatory risk, and boosting chances of success.
Marker Therapeutics News
MRKR FAQ
What was Marker Therapeutics’s price range in the past 12 months?
Marker Therapeutics lowest stock price was $0.95 and its highest was $5.95 in the past 12 months.
What is Marker Therapeutics’s market cap?
Marker Therapeutics’s market cap is $14.14M.
When is Marker Therapeutics’s upcoming earnings report date?
Marker Therapeutics’s upcoming earnings report date is Aug 18, 2025 which is in 2 days.
How were Marker Therapeutics’s earnings last quarter?
Currently, no data Available
Is Marker Therapeutics overvalued?
According to Wall Street analysts Marker Therapeutics’s price is currently Undervalued.
Does Marker Therapeutics pay dividends?
Marker Therapeutics does not currently pay dividends.
What is Marker Therapeutics’s EPS estimate?
Marker Therapeutics’s EPS estimate is -0.3.
How many shares outstanding does Marker Therapeutics have?
Marker Therapeutics has 11,314,835 shares outstanding.
What happened to Marker Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Marker Therapeutics?
Currently, no hedge funds are holding shares in MRKR
Marker Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (534.92% Upside)
$8.00 (534.92% Upside)
Hedge Fund Trend
Increased
By 328.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 10.5%
Last 30 Days ▲ 10.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.80%
12-Months-Change
Fundamentals
Return on Equity
-97.30%
Trailing 12-Months
Asset Growth
20.59%
Trailing 12-Months
Company Description
Marker Therapeutics
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.
MRKR Stock 12 Month Forecast
Average Price Target
$8.00
▲(534.92% Upside)
Technical Analysis
Ibio
―
Moleculin Biotech
―
ABVC BioPharma
―
Addex Therapeutics
―
Allarity Therapeutics
―
Ownership Overview
41.03% Insiders
3.14% Mutual Funds
29.22% Other Institutional Investors
24.20% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---